Formulating a heat- and shear-labile drug in an amorphous solid dispersion: Balancing drug degradation and crystallinity

• Prif Awduron: Daniel A. Davis, Jr (Awdur), Dave A. Miller (Awdur), Supawan Santitewagun (Awdur), J. Axel Zeitler (Awdur), Yongchao Su (Awdur), Robert O. Williams, III (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: Elsevier, 2021-12-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

We seek to further addresss the questions posed by Moseson et al. regarding whether any residual crystal level, size, or characteristic is acceptable in an amorphous solid dispersion (ASD) such that its stability, enhanced dissolution, and increased bioavailability are not compromised. To address th...